Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634441 | 1.00 | PTPN1 (0.56) | PTPN1GSK3BGAACES2KDM4E | |
| SCHEMBL3916517 | 0.86 | PTPN1 (0.56) | PTPN1GSK3BGAACES2KDM4E | |
| SCHEMBL8369756 | 0.84 | GAA (0.51) | PTPN1GSK3BGAACES2KDM4E | |
| SCHEMBL30006617 | 0.83 | PTPN1 (0.56) | PTPN1GSK3BGAACES2KDM4E | |
| SCHEMBL21462078 | 0.83 | PTPN1 (0.56) | PTPN1GSK3BGAACES2KDM4E | |
| SCHEMBL2075208 | 0.83 | GAA (0.54) | GAACES2KDM4EALDH1A1HPGD | |
| SCHEMBL2097720 | 0.83 | CES2 (0.66) | PTPN1GSK3BCES2KDM4EALDH1A1 | |
| SCHEMBL7786271 | 0.83 | PTPN1 (0.56) | PTPN1GSK3BGAACES2KDM4E | |
| SCHEMBL18758206 | 0.83 | GAA (0.50) | PTPN1GSK3BGAACES2KDM4E | |
| SCHEMBL9526674 | 0.81 | PTPN1 (0.54) | PTPN1GSK3BCES2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362446-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | INDIVIOR UK LIMITED (GB) | 2020-03-03 | — | — | US | disclosed |
| US-20180297990-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR INC. | 2018-10-18 | — | — | US | disclosed |
| EP-3362446-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | Indivior UK Limited (GB) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017064488-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | INDIVIOR UK LIMITED (GB) | 2017-04-20 | — | — | WO | disclosed |
| EP-2265606-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-2758380-B1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-9073881-B2 | Benzoic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2758380-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-20130079346-A1 | BENZOIC ACID DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2013-03-28 | — | — | US | disclosed |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| WO-2009129109-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-22 | — | — | WO | disclosed |
| US-7504520-B2 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBOTT LABORATORIES (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1885704-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | Abbott Laboratories (US) | 2008-02-13 | — | — | EP | disclosed |
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | ABBVIE INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006122250-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2006-11-16 | — | — | WO | disclosed |
| EP-0735142-B1 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICALS CO LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0145314-A1 | Antifungal triazole compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577361-B2 | Dopamine D3 receptor antagonists having a morpholine moiety | DRD3, DRD2, SLC6A3 | PTPN1 1167/4885GSK3B 1218/4885GAA 1426/4885 |
| US-20060281799-A1 | Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof | TRPV1, TMEM109, CACNA1E | PTPN1 900/4885GSK3B 4228/4885GAA 3736/4885 |
| US-20180297990-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A MORPHOLINE MOIETY | DRD3, DRD2, SLC6A3 | PTPN1 1167/4885GSK3B 1218/4885GAA 1426/4885 |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | PTPN1 1786/4885GSK3B 1521/4885GAA 175/4885 |
| US-20130079346-A1 | BENZOIC ACID DERIVATIVES | EIF4EBP1, EIF4E, EIF4A2 | PTPN1 3778/4885GSK3B 2874/4885GAA 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.